Abstracts Archive - Page 1679 of 2607 - ACR Meeting Abstracts

Abstract Number: 1194 • 2016 ACR/ARHP Annual Meeting
Low Body Mass Index and Smoking Are Associated with a Lower Risk of Sarcoidosis: A Population-Based Nested Case-Control Study
Patompong Ungprasert¹, Cynthia S. Crowson² and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN
Low Body Mass Index and Smoking Are Associated With a Lower Risk of Sarcoidosis: A Population-Based Nested Case-Control Study Background/Purpose: Sarcoidosis is a systemic disorder…
Abstract Number: 1195 • 2016 ACR/ARHP Annual Meeting
Risk of Hospitalized Infection Among Patients with Sarcoidosis: A Population-Based Retrospective Cohort Study
Patompong Ungprasert¹, Cynthia S. Crowson² and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN
Risk of Hospitalized Infection Among Patients With Sarcoidosis: A Population-Based Retrospective Cohort Study Background/Purpose: Increased risk of infection has been observed in several autoimmune disorders. …
Abstract Number: 1196 • 2016 ACR/ARHP Annual Meeting
AA Amyloidosis: An Evaluation of Epidemiology and Prevalence in the US and EU5 Countries
WIlliam Andrews¹, Denis Garceau², Tomascz Sablinski³, Paul Zhang⁴ and Todd Waldman⁴, ¹Auven Therapeutics, Hopkinton, MA, ²Auven Therapeutics, Montreal, QC, Canada, ³Auven Therapeutics, St. Thomas, Virgin Islands (U.S.), ⁴Navigant Consulting, Inc., New York City, NY
Background/Purpose: AA amyloidosis (AAA) is a rare, systemic form of amyloidosis, which mostly occurs secondary to chronic inflammatory conditions, predominantly systemic arthritides. AAA is characterized…
Abstract Number: 1197 • 2016 ACR/ARHP Annual Meeting
Certain Serum Micro-RNAs Are Associated with Osteoarthritis
Jean-Charles Rousseau¹, Elisabeth Sornay-Rendu¹, Olivier Borel¹ and Roland Chapurlat², ¹INSERM UMR 1033, Lyon, France, ²Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, INSERM UMR 1033 and Université de Lyon and Hospices Civils de Lyon, Lyon, France
Background/Purpose: Sensitive and specific blood biomarkers to detect the initial stages of osteoarthritis (OA) and to predict the future development of the disease are not…
Abstract Number: 1198 • 2016 ACR/ARHP Annual Meeting
Gene Enrichment Analysis Identifies Active CD40-CD40L Signaling in Early and Established Rheumatoid Arthritis
Yanxia Guo¹, Alice Walsh¹, Ursula Fearon², Malcolm D. Smith³, Mihir D Wechalekar⁴, Xuefeng Yin¹, Suzanne Cole¹, Carl Orr⁵, Trudy McGarry⁵, Mary Canavan⁵, Stephan Kelly⁶, Costantino Pitzalis⁷, Tai-An Lin¹, Xuejun Liu¹, Susanna Proudman⁸, Douglas J. Veale⁹ and Sunil Nagpal¹, ¹Immunology, Janssen Research & Development, Spring House, PA, ²St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ³Flinders University, Adelaide, Australia, ⁴Royal Adelaide Hospital, Adelaide, Australia, ⁵St. Vincent's University Hospital, Dublin, Ireland, ⁶Queen Mary University of London, London, United Kingdom, ⁷Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁸University of Adelaide, Adelaide, Australia, ⁹Consultant Rheumatologist, Centre for Arthritis and Rheumatic Disease, St. Vincent’s University Hospital and University College Dublin, Dublin 4, Ireland
Background/Purpose: CD40 and CD40L (CD154) are tumor necrosis factor (TNF) family members involved in the pathogenesis of various autoimmune diseases. While this pathway is active…
Abstract Number: 1199 • 2016 ACR/ARHP Annual Meeting
A Genome-Wide Association Study of Methotrexate-Pneumonitis in Rheumatoid Arthritis: Results from the Pneumonitis Study Consortium
James Bluett¹, Sally-Ann Owen¹, Jonathan Massey², Darren Plant², Munir Pirmohamed³, Suzanne M.M. Verstappen⁴ and Anne Barton^5,6, ¹Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁵NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK, Manchester, United Kingdom
Background/Purpose: Methotrexate (MTX) is associated with a rare but potentially life-threatening lung disease, MTX-pneumonitis (MTX-P). MTX-P is an idiosyncratic hypersensitivity reaction to MTX inducing inflammation,…
Abstract Number: 1200 • 2016 ACR/ARHP Annual Meeting
Transcriptional Profiling of Early RA Synovial Tissue Reveals the Impact of Triple DMARD Treatment on T Cell Activation Pathways
Alice M Walsh¹, Sunil Nagpal¹, Mihir D Wechalekar², Yanxia Guo¹, Xuefeng Yin¹, Helen Weedon², Susanna Proudman³ and Malcolm D. Smith², ¹Immunology, Janssen Research & Development, Spring House, PA, ²Flinders University, Adelaide, Australia, ³University of Adelaide, Adelaide, Australia
Background/Purpose: While several transcriptional profiling studies of synovial biopsies have been reported from RA patients with advanced disease, there is relatively little data available from…
Abstract Number: 1201 • 2016 ACR/ARHP Annual Meeting
Deconvolution of Immune Cell Proportions from Whole Blood RNA Using Next-Generation Sequencing
Omar Jabado¹, Sarah Hu², Julie Carman³, Suzanne Suchard³, Deborah Lee⁴, Zhenhao Qi⁵, Stefan Kirov⁶, Ryan Golhar⁷, Aiqing He⁷, Cate Speake⁸, Peter S. Linsley⁸, Steven G. Nadler⁹ and Somnath Bandyopadhyay², ¹3551 Lawrenceville Princeton, Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Princeton, NJ, ³Discovery Translational Sciences Group, Bristol-Myers Squibb, Princeton, NJ, ⁴Discovery Immunoscience, Bristol-Myers Squibb, Princeton, NJ, ⁵Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, ⁶Genetically Defined Diseased & Genomics, Bristol-Myers Squibb, Princeton, NJ, ⁷Genetically Defined Diseases & Genomics, Bristol-Myers Squibb, Princeton, NJ, ⁸Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁹Immunosciences Translational Research, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Measurements of immune cell proportions from whole blood can be used to detect pharmacodynamic effects, as a marker for prognosis and to aid in…
Abstract Number: 1202 • 2016 ACR/ARHP Annual Meeting
Characteristic Compositional and Functional Alteration of Gut Microbiota in Patients with Behcet’s Disease
Noboru Suzuki¹, Jun Shimizu² and Takao Kubota³, ¹Department of Immunology and medicine, St. Marianna University School of Medicine, Kawasaki-shi, 216-8511, Japan, ²Department of Immunology and Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³The Japan Self Defense Forces Central Hospital, Tokyo, Japan
Background/Purpose: We have presented evidence that the frequency of helper T (Th)17 cells increased and the cells had already been activated in vivo in patients…
Abstract Number: 1203 • 2016 ACR/ARHP Annual Meeting
Differential Synovial Expression Patterns in Early Osteoarthritis Predict Pain and Progression of Joint Damage
Arjen B. Blom¹, Martijn H. van den Bosch¹, Hans Cats², F van den Hoogen³, Floris PJ Lafeber⁴, Wim B. van den Berg¹, Peter L. van Lent¹ and Peter M. van der Kraan¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Hengstdal 3, Sint Maartenskliniek, Ubbergen, Netherlands, ³Rheumatology, Radboud UMC, Nijmegen, Netherlands, ⁴Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: The cause for chronic pain in OA is largely unknown. Over 50% of osteoarthritis (OA) patients show synovial inflammation, even at early stages of…
Abstract Number: 1204 • 2016 ACR/ARHP Annual Meeting
Methotrexate Is an Antibacterial Drug Metabolized By Human Gut Bacteria
Renuka R. Nayak^1,2, Colleen O'Loughlin³, Michael Fischbach⁴ and Peter J. Turnbaugh⁵, ¹Department of Microbiology & Immunology, University of California, San Francisco, San Francisco, CA, ²Department of Medicine, UCSF, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, ⁴Department of Bioengineering and Therapeutic Sciences,, University of California, San Francisco, San Francisco, CA, ⁵Microbiology and Immunology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology that causes inflammation and irreversible damage in joints and other organs. Methotrexate (MTX) is…
Abstract Number: 1205 • 2016 ACR/ARHP Annual Meeting
In silico Drug Repurposing Analysis Supports Phosphoinositol 3 Kinase Inhibitors As Treatment of LUPUS
Daniel Toro¹, Pedro Carmona Sanz² and Marta Alarcón-Riquelme^3,4, ¹Bioinformatics and Medical Genomics, Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Ganada, Spain, ²Unit of Bioinformatics, Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain, ³Center for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Andalusian Regional Government, Health Sciences Technology Park, Granada, Spain, ⁴Unit for Chronic Inflammatory Diseases, Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a clinically heterogeneous disease with few treatment options. Current treatments are not fully effective and show highly variable responses.…
Abstract Number: 1206 • 2016 ACR/ARHP Annual Meeting
A Replication Study and Meta-Analysis Demonstrate the Influence of the mtDNA Haplogroups in the Rate of Incident Knee Osteoarthritis. Functional Explanation of This Association Using Transmitochondrial Cybrids
Ignacio Rego-Pérez¹, Mercedes Fernandez Moreno¹, Angel Soto-Hermida¹, Maria Eugenia Vazquez Mosquera¹, Estefanía Cortés-Pereira¹, Sara Relaño-Fernandez², Tamara Hermida-Gómez³, Sonia Pertega⁴, Rafael Garesse⁵, Natividad Oreiro³, Carlos Fernandez-Lopez¹ and Francisco J. Blanco^1,6, ¹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ²Plataforma de Genómica. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ³Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ⁴Unidad de Epidemiología Clínica y Bioestadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ⁵Departamento de Bioquímica, Instituto de Investigaciones Biomédicas "Alberto Sols" UAM-CSIC y Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidad Autónoma de Madrid 28029, Madrid, Spain, Madrid, Spain, ⁶Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruña, Spain
Background/Purpose: The study of the mitochondria in the context of osteoarthritis (OA) attracted much attention. In this study we aimed to evaluate the influence of…
Abstract Number: 1207 • 2016 ACR/ARHP Annual Meeting
Design of a Multiplex Serum Proteome Assay to Monitor Biologic Drug Response in Rheumatoid Arthritis Patients
Niamh Callan¹, Aisha Butt¹, Stephen R. Pennington², Cathy McGeough³, Philip Gardiner⁴, Gary Wright⁵, Tony Bjourson³ and David S. Gibson⁶, ¹Proteome Research Centre, Conway Institute, University College Dublin, Dublin, Ireland, ²Proteome Research Centre, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ³Northern Ireland Centre for Stratified Medicine, Ulster University, Londonderry, United Kingdom, ⁴Rheumatology, Altnagelvin Hospital, Londonderry, United Kingdom, ⁵Rheumatology, Musgrave Park Hospital, BELFAST, United Kingdom, ⁶Inflammatory Disease Research Group, Northern ireland Centre for Stratified Medicine, Ulster University, Londonderry, United Kingdom
Background/Purpose: Biologic drugs have revolutionised the treatment of Rheumatoid Arthritis (RA), however these therapies are expensive and exhibit a high non–response rate (30%). Currently there…
Abstract Number: 1208 • 2016 ACR/ARHP Annual Meeting
High-Throughput Screening Discovers Multiple Novel Autoantibodies in Rheumatoid Arthritis, Systemic Lupus, Systemic Sclerosis and Sjogrens Syndrome
Peter Schulz-Knappe¹, Hans-Dieter Zucht¹, Petra Budde¹, Heike Göhler¹, Daniel Wirtz¹, Johannes Schulte-Pelkum¹, Stefan Vordenbäumen², Torsten Witte³ and Prof. Dr. Matthias Schneider⁴, ¹Protagen AG, Dortmund, Germany, ²Rheumatology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ³Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ⁴Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany
Background/Purpose: Diagnostic biomarkers are decision-making tools in clinical lab routine and are of growing importance for clinical management of patients. In autoimmune diseases, one important…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].